For antibody validation, the combination of niflumic acid (100 μM) and ciglitazone 7.5 μM was employed as a positive control, as it has been shown to induce significant phosphorylation of PERK and eIF2α in A549 lung cancer cells in previous research [26]. The gene discussed is EIF2AK3; the disease is lung carcinoma.